Overview
Pharmaceutical

Solasia Pharma K.K.

Solasia Pharma is an oncology-focused specialty pharmaceutical company engaged in the development and commercialization of innovative medicines for cancer treatment and management of cancer therapy-related side effects across Japan and Asian markets including China and South Korea. The company in-licenses drug and medical device candidates at various clinical stages, conducts clinical development primarily in Japan and Asia, and generates revenue through product sales, out-licensing, milestones, and royalties. Its current marketed products include Darbias (SP-02) for peripheral T-cell lymphoma in Japan and Episil (SP-03), a medical device for oral mucositis pain relief, approved in Japan, China, and South Korea.

Market Cap
¥7.37B
US$47.0M
EV
¥6.08B
US$38.8M
Stock¥27▲+3.85%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
5.1
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-44.2%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Aug 14, 26Q2 FY2026/12 earnings announced
MC → EV Bridge
7.37BUS$47.0MMarket Cap0.08BUS$0.50M+ Debt1.29BUS$8.22M− Cash0.08BUS$0.49M− Inv. Sec.6.08BUS$38.8MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.56US$3.57M'21/121.09US$6.96M'22/120.62US$3.93M'23/120.32US$2.02M'24/120.43US$2.74M'25/12
EBITDA 5Y (¥B)
-1.92-US$12.3M'21/12-1.94-US$12.3M'22/12-0.64-US$4.08M'23/12-1.76-US$11.2M'24/12-0.82-US$5.26M'25/12
Net Income 5Y (¥B)
-2.48-US$15.8M'21/12-2.55-US$16.3M'22/12-1.11-US$7.09M'23/12-1.94-US$12.4M'24/12-0.88-US$5.59M'25/12
Capital Structure
95%
EquityD/E 0.05xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
0.71US$4.55M0.08US$0.54M'21/120.80US$5.12M0.04US$0.24M'22/120.73US$4.64M0.06US$0.38M'23/120.89US$5.65M0.03US$0.16M'24/121.39US$8.85M0.10US$0.61M'25/12
Shareholders
Top 10 hold 13.8%
1
NIPPON KAYAKU CO.,LTD.
4.38%
2
Maruho Co., Ltd.
4.14%
3
MATSUI SECURITIES CO.,LTD.
0.77%
4
SBI SECURITIES Co., Ltd.
0.76%
5
NOMURA INTERNATIONAL PLC A/C JAPAN FLOW
0.76%
6
Hiroya SENO
0.73%
7
Yoshihiro ARAI
0.62%
8
Hiroyuki ISOGAI
0.57%
9
Namiko KATO
0.56%
10
Japan Securities Finance Co.,Ltd.
0.52%
Management
8 officers
Yoshihiro ARAI
Representative Director, President
Apr 1985 Joined Searle Pharma K.K. (now Pfizer Japan Inc.) Feb 1994 Joined Amgen K.K., Director, Clinical Development Department, Development Division Apr 2007 Director, Product Planning Department, Development Division, Amgen K.K. Sep 2007 Joined JapanBridge Inc. (now PeptiDream Inc.), General Manager and Head of Development Division Feb 2013 Representative Director, President, the Company (current)
1960-07-27
Toshio MIYASHITA
Director, CFO and General Manager, Administration Division
Sep 1997 Joined Innotech K.K. Jan 1999 Seconded to Admonscience K.K., General Manager, Administration Division May 2003 Joined Sosei Co., Ltd. (now Nxera Pharma Co., Ltd.), Vice President, Corporate Planning Department Nov 2005 Seconded to Arakis Limited, Vice President, Corporate Planning Department Mar 2007 Director and Partner, Hibiki Partners K.K. May 2007 Audit & Supervisory Board Member, Atani Corporation Apr 2008 Audit & Supervisory Board Member, Value Pharma Co., Ltd. Aug 2009 CFO, J-Pharma Co., Ltd. Nov 2011 Acting CFO, the Company Apr 2012 Director and CFO, J-Pharma Co., Ltd. Jan 2014 Joined the Company, CFO and General Manager, Administration Division Dec 2015 Director, CFO and General Manager, Administration Division, the Company (current)
1967-11-25
Stanley LOW
Director
Jun 1981 Joined Pfizer Corp. Hong Kong Apr 1987 Managing Director, Merck & Co. Oct 1994 Joined Schering-Plough China Ltd., General Manager Oct 1998 Vice President, Pharmacia / Searle Asia Area Jul 2002 Joined Baxter Healthcare International China, General Manager Apr 2009 Managing Director, Haopy Pharmaceuticals Co., Ltd. Nov 2010 President, China Biologic Products, Inc. Mar 2012 COO, Eddingpharm Ltd. Mar 2013 CEO, Amsino Medical Group Dec 2014 Outside Director, the Company (current) Mar 2015 Executive Partner, BizPro International LLC (current) May 2015 Senior Advisor, Wuxi SiFong Information Technology Co., Ltd. (current) Jun 2017 Outside Director, Xian Libang Pharmaceutical (current)
1954-08-30
Norikazu SAKAEKI
Director
Apr 1969 Joined Shell Sekiyu K.K. (now SR Energy K.K.) Jun 1973 Joined Matsushita Electric Works, Ltd. (now Panasonic Holdings Corporation) Aug 1979 Joined Nihon Ciba-Geigy K.K. (now Novartis Pharma K.K.), General Manager, Corporate Planning Department Jan 1994 Joined Bayer Yakuhin, Ltd., General Manager, Technical Operations Department Mar 1997 Director and Head of Shiga Plant, Bayer Yakuhin, Ltd. Jul 2002 Representative Director, President, Bayer Yakuhin, Ltd. Jan 2007 Representative Director, Chairman, Bayer Yakuhin, Ltd. Apr 2010 Director, Chairman, Bayer Yakuhin, Ltd. May 2014 Outside Director, AnGes MG, Inc. (now AnGes, Inc.) (current) Jun 2014 Advisor, CM Plus Inc. (current) Jan 2015 Representative Partner, Eiki Consulting LLC (current) Mar 2015 Chairman of the Board, FunPep Co., Ltd. Jun 2015 Outside Director, Towa Pharmaceutical Co., Ltd. (current) Apr 2016 Outside Director, the Company (current) Jan 2017 Outside Director, FunPep Co., Ltd. (current) Jun 2018 Outside Director, Gene Techno Science Co., Ltd. (now Kidswell Bio Inc.) (current) Aug 2023 Outside Director, AwakApp Inc. (current)
1948-04-17
Jiro MIZUKAWA
Director
Apr 1976 Joined Malpy Searle K.K. (now Pfizer Japan Inc.) Nov 1989 Product Manager and Osaka Branch Manager, Searle Pharma K.K. (now Pfizer Japan Inc.) Aug 1992 Deputy Head of Sales Division, Nihon Monsanto K.K. (now Pfizer Japan Inc.) Jul 1995 Sales Manager, CNS & General Care, Pharmacia & Upjohn K.K. (now Pfizer Japan Inc.) Jul 1999 Sales Manager, CNS & General Care and Distribution Policy Manager, Pharmacia K.K. (now Pfizer Japan Inc.) Feb 2003 CNS Sales Manager, Boehringer Ingelheim Japan, Ltd. Dec 2003 Executive Officer, Oncology & Specialty Care, Sanofi-Aventis K.K. (now Sanofi K.K.) Nov 2009 Managing Director, Head of Pharmaceuticals Division, Abbott Japan LLC (now AbbVie GK) Aug 2016 Representative Director, LTL Pharma Co., Ltd. Mar 2020 Outside Director, the Company (current) Jul 2021 Chairman of the Board, LTL Pharma Co., Ltd. Jul 2022 Special Advisor, LTL Pharma Co., Ltd. (current)
1952-09-14
Susumu ARAKI
Full-time Audit & Supervisory Board Member
Apr 1976 Joined Tokai Bank, Ltd. (now MUFG Bank, Ltd.) Jun 1996 Branch Manager, Labuan Branch, Tokai Bank, Ltd. Jun 2001 Branch Manager, Kamata Branch, Tokai Bank, Ltd. Jun 2002 Joined Qol Co., Ltd., Manager, Corporate Planning Office and Finance Department Jun 2004 Director, Qol Co., Ltd. Jun 2008 Senior Managing Director, Qol Co., Ltd. Mar 2019 Outside Audit & Supervisory Board Member, the Company (current)
1952-08-06
Nagisa KAWAIDA
Audit & Supervisory Board Member
Dec 2015 Registered as attorney-at-law (Daiichi Tokyo Bar Association) Jan 2016 Joined Yodoyabashi-Yamagami Law Office Apr 2021 Partner, Yodoyabashi-Yamagami Law Office (current) May 2021 Research Officer (part-time), Civil Affairs Bureau, Ministry of Justice Jul 2021 Arbitration and Compliance Committee Member (part-time), Japan Women's Basketball League (general incorporated association) (current) Mar 2024 Outside Audit & Supervisory Board Member, the Company (current) Oct 2025 Auditor (part-time), En Scholarship and Grant Foundation (general incorporated foundation) (current)
1989-07-21
Eisaku NAKAMURA
Audit & Supervisory Board Member
Apr 1987 Joined Marubeni Corporation Apr 2001 Representative Director, President, Berebuno Co., Ltd. Sep 2002 Outside Director, Canvas Co., Ltd. Sep 2006 Director and Tokyo Branch Manager, Bio Site Capital Co., Ltd. Sep 2013 Director, Koinobori Association (general incorporated association) May 2015 Outside Director, Acucela Inc. (now Kubota Vision Inc.) Mar 2016 Outside Director, Kubota Pharmaceutical Holdings Co., Ltd. Feb 2017 Auditor, Koinobori Association (general incorporated association) (current) Mar 2018 Outside Director, De Western Therapeutics Institute Co., Ltd. Mar 2023 Outside Director, Audit and Supervisory Committee Member, De Western Therapeutics Institute Co., Ltd. (current) Mar 2025 Outside Audit & Supervisory Board Member, the Company (current)
1961-07-01
Large Shareholding Reports
Macquarie Bank Limited
2026-01-16
6.12%→4.45%
Macquarie Bank Limited
2026-01-08
7.38%→6.12%
Macquarie Bank Limited
2025-11-28
8.49%→7.38%
Macquarie Bank Limited
2025-08-29
9.73%→8.49%
Macquarie Bank Limited
2025-08-06
11.62%→9.73%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-13
Q2 Earnings Flash
FY ending Dec 2026
EDINET
2026-08-13
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-05-15
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-24
Annual Securities Report
Period: Jan 2025 – Dec 2025
EDINET
2026-01-16
Large Shareholding Report
EDINET
2026-01-08
Large Shareholding Report
EDINET
2025-11-28
Large Shareholding Report
TDnet
2025-11-14
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-29
Large Shareholding Report
EDINET
2025-08-13
Semi-Annual Securities Report
Period: Jan 2025 – Jun 2025
EDINET
2025-08-06
Large Shareholding Report
TDnet
2025-05-14
Q1 Earnings Flash
FY ending Dec 2025
EDINETAmended
2025-03-31
Amended Securities Registration Statement
EDINET
2025-03-26
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINETAmended
2025-03-26
Amended Securities Registration Statement
EDINET
2025-03-24
Securities Registration Statement
EDINET
2024-08-14
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-15
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-22
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-05-15
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-23
Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINETAmended
2022-08-18
Amended Quarterly Securities Report
EDINET
2022-08-15
Quarterly Securities Report
EDINET
2022-05-13
Quarterly Securities Report
EDINET
2022-03-24
Annual Securities Report
EDINET
2021-11-10
Quarterly Securities Report
EDINET
2021-08-11
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →